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Editorial on the Research Topic
Bone: Endocrine Target and Organ
Bone is essential for mobility, calcium homeostasis, and hematopoietic function. Recently, advances 
in bone biology have highlighted the importance of skeleton as an endocrine organ (1). In fact, hor-
mones produced by bone cells can control mineral ion homeostasis (i.e., FGF23) and energy balance 
(i.e., osteocalcin). Naturally, bone is the target organ of different endocrine glands or tissues through 
numerous hormones and/or molecules as glucagon-like peptide-1 (GLP-1), PTH, adipokines as well 
as cytokines produced by immune cells. The articles in this topic highlight the effect of molecules 
released by gut, parathyroids, adipose tissues and immune system on bone remodeling.
In detail, GLP-1, produced and secreted by intestinal enteroendocrine L-cells, can enhance 
bone mineral density and improve bone quality but the specific mechanism and related molecular 
pathways are still not completely understood (2–5). Zhao et  al. focused on the current state of 
research into the impact of GLP-1 on bone metabolism reporting that GLP-1 increases the number 
of osteoblasts and promotes the expression of genes related to bone formation (6). Zhao et al. also 
described that GLP-1 is also associated with increased serum levels of bone formation markers, 
including alkaline phosphatase, osteocalcin, and N-terminal propeptide of type I procollagen 
(P1NP). In general, GLP-1 may inhibit osteoclastic bone resorption. However, the specific molecu-
lar mechanisms responsible for the effects of GLP-1 have still not been fully elucidated.
Our special issue also included a review of the management of primary hyperparathyroidism 
(PHPT), a disease characterized by chronic overproduction of PTH. This hormone is a key regulator 
of bone remodeling and its overproduction is a common cause of bone loss, causes osteoporosis 
and is an independent risk factor for fractures. This clinical condition is of wide interest for both 
pathophysiological mechanisms leading to bone loss and clinical aspects of the disease; as regards 
pathophysiology of bone loss, an increase of the inflammatory cytokine IL-17 during PHPT in 
humans and in mice has been recently described (7). A clinical debate point is on the efficacy and 
indication for treatment of PHPT in asymptomatic disease. In this special issue, Leere et al. and 
Leere et al. by a systematic review provide an overview of the existing literature on contemporary 
pharmaceutical options available for the medical management of PHPT. The reviews by Leere et al. 
and Leere et al. illustrate the strengths and drawbacks of the pharmaceutical agents that are available 
at present and highlight a significant decrease of effect on plasma calcium both for bisphosphonates 
and, with different timing, for cinacalcet. The latter did not seem to have major effects on bone 
density and turnover, whereas long-term treatment with bisphosphonates seemed to increase bone 
density.
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Recently, numerous researchers deepened bone and adipose 
tissue interactions because numerous adipokines regulated 
bone remodeling in physiological and pathological conditions. 
The research article provided in this special issue by Lecka-
Czernik et  al. further highlighted this issue. Marrow adipose 
tissue (MAT) is distinctive with respect to origin, function and 
metabolism. MAT has high heterogeneity which is linked to 
skeletal location and bone metabolism. MAT has features of 
both white (WAT)- and brown (BAT)-like or beige adipose 
tissue. Lecka-Czernik et  al. reported that MAT near the tra-
becular bone of proximal tibia (pMAT) expressed high levels 
of beige fat markers, with respect to MAT located in distal tibia 
(dMAT). The same authors also found that in males higher 
trabecular bone mass is related to lower pMAT volume and 
higher expression of beige markers in the same location, with 
respect to females. Ovariectomy resulted in reduced cortical 
and trabecular bone mass and augmented pMAT and dMAT 
volume. Otherwise in males, orchiectomy determined cortical 
and trabecular bone loss and the trend to enlarged volume of 
both pMAT and dMAT.
Bone-immune system cross-talk also attracts numerous 
scientists (8, 9) and Leere et al. Persistent systemic inflammation 
can lead to heterotopic ossification, a disease lacking of successful 
treatment strategies. In this preliminary study, in the saliva, Sung 
Hsieh et al. characterized the diagnostic potential of MCP-1 and 
VEGF cytokines that may serve as biomarkers for an early stage 
diagnosis of heterotopic ossification.
In conclusion, all the articles provided a comprehensive 
overview of the mechanisms regulating bone remodeling. It is 
fundamental in order to highlight the pathophysiology of bone 
disease and thus identify new therapeutic targets.
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